These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 14665352)

  • 1. Evidence of increased prostate cancer detection in men aged 50 to 59: a review of 324,684 biopsies performed between 1995 and 2002.
    Lowe FC; Gilbert SM; Kahane H
    Urology; 2003 Dec; 62(6):1045-9. PubMed ID: 14665352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].
    Cepeda Piorno J; Rivas del Fresno M; Fuente Martín E; González García E; Muruamendiaraz Fernández V; Fernández Rodríguez E
    Arch Esp Urol; 2005 Jun; 58(5):403-11. PubMed ID: 16078781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.
    Jacobsen SJ; Katusic SK; Bergstralh EJ; Oesterling JE; Ohrt D; Klee GG; Chute CG; Lieber MM
    JAMA; 1995 Nov; 274(18):1445-9. PubMed ID: 7474190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of PSA increase with and without prostate cancer.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Urology; 2003 Jul; 62(1):64-9. PubMed ID: 12837424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma.
    el-Galley RE; Petros JA; Sanders WH; Keane TE; Galloway NT; Cooner WH; Graham SD
    Urology; 1995 Aug; 46(2):200-4. PubMed ID: 7542822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
    Valberg M; Grotmol T; Tretli S; Veierød MB; Moger TA; Devesa SS; Aalen OO
    Eur J Epidemiol; 2017 Jun; 32(6):511-520. PubMed ID: 27431530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL.
    Kim HS; Jeon SS; Choi JD; Kim W; Han DH; Jeong BC; Seo SI; Lee KS; Lee SW; Lee HM; Choi HY
    Urology; 2010 Oct; 76(4):919-22. PubMed ID: 20303152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis].
    van der Kwast TH; Hoedemaeker RF; Schröder FH
    Ned Tijdschr Geneeskd; 2005 Apr; 149(18):972-6. PubMed ID: 15903037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
    J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Transrectal prostatic biopsy management policy for patients older than 50 years in relation to PSA values elaborated by a mathematical decision tree].
    Santos Arrontes D; Cortés Aránguez I; Begara Morillas F; Fernández Arjona M; de Castro Barbosa F
    Arch Esp Urol; 2005 Jun; 58(5):413-6. PubMed ID: 16078782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of prostate cancer in the Umbria region of Italy: evidence of opportunistic screening effects.
    La Rosa F; Stracci F; Minelli L; Mastrandrea V
    Urology; 2003 Dec; 62(6):1040-4. PubMed ID: 14665351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
    Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
    Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
    Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
    Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.